Hey, How About Starship Earth?

By KIM BELLARD I missed the job announcement on the company website.  I missed it again when the company posted the job on Linkedin.  I missed it when Eric Ralph tweeted that the posting was “probably the coolest job posting I’ve read in years.”  Fortunately, though, I follow Isaac Kohne (MD, PhD), and I did… Read More »

Incyte the latest to fall victim to JAK scrutiny as FDA pushes back Jakafi review in GVHD

The entire JAK inhibitor family of medicines is feeling the ripple effects from a safety signal flagged for Pfizer’s Xeljanz. Now, the first marketed drug in the class is encountering increased scrutiny from the FDA. The FDA has pushed back a decision for Incyte’s application for Jakafi in steroid-refractory chronic graft-versus-host disease (GVHD) by three months, the… Read More »